Covid19: Impact Survey

an international online survey to determine the impact of the COVID-19 pandemic on caregivers and patients with myeloma and precancerous conditions such as MGUS and MBL.

Take Covid19 Impact Survey

Related conditions

Although Myeloma UK primarily provides information, support and practical advice relating to myeloma, we also provide a range of information on related conditions.

If you would like to talk to someone about any aspect of these related conditions and their treatment and management, call the Myeloma Infoline.

AL amyloidosis
A condition in which an abnormal protein, usually produced by cells in the bone marrow, deposits and accumulates in the tissues and organs of the body. Find out more

Solitary plasmacytoma
A localised build-up of abnormal plasma cells that occurs either inside or outside the bone. Find out more

Monoclonal Gammopathy of Undetermined Significance (MGUS)
A condition characterised by the presence of an abnormal protein in the blood and/or urine, called paraprotein. Find out more

Smouldering myeloma
Also known as asymptomatic myeloma, smouldering myeloma is a very slow-growing type of myeloma. Find out more

Plasma Cell Leukaemia (PCL)
Plasma cell leukaemia (PCL) is a rare type of cancer arising from plasma cells, it belongs to the same spectrum of haematological disorders as myeloma. Find out more

POEMS syndrome is a rare type of a plasma cell disorder that can affect multiple systems in the body. POEMS syndrome is also known as osteosclerotic myeloma, Takatsuki syndrome and Crow-Fukase syndrome however these terms are less commonly used. Find out more

AL amyloidosis

The term amyloidosis is a generic term used for a group of diseases where an abnormal protein is produced. The abnormal protein can build up in various organs or tissues and cause problems.

In AL amyloidosis, abnormal plasma cells in the bone marrow produce an abnormal protein called amyloid. This abnormal protein is only broken down very slowly by the body and starts to build up in the tissues and organs. The build up of amyloid in these tissues and organs gradually damages their function and causes symptoms. The build up of amyloid protein is called an ‘amyloid deposit’.

Amyloid deposits can build up almost anywhere in the body. Each patient has a different pattern of amyloid deposition, with different organs affected. Amyloid can build up in the kidneys, heart, liver, spleen, nerves, or digestive system, and may affect two or more organs at the same time. AL amyloidosis does not affect the brain.

AL amyloidosis is a relatively rare disease, with approximately 500 – 600 people diagnosed in the UK each year. Treatments for AL amyloidosis can be very effective at halting its progress. However there is currently no cure.

How We Can Help

AL amyloidosis information
Provides information about AL amyloidosis, its treatment and management. Also includes information on a range of specific topics relating to living with AL amyloidosis, such as diet and nutrition, travel insurance and setting up a support group.


Additional Myeloma Resources/Links


Meet the Team behind Myeloma Ireland

Patrick Hayden

Patrick Hayden Chair

Mary Kelly

Mary Kelly Vice-Chair

Maura Dowling

Maura Dowling Secretary

Liam McManuse

Liam McManuse Treasurer

Anne Fitzgerald

Anne Fitzgerald Assistant Treasurer

Peter O’Gorman

Peter O’Gorman

Joe O’Brien

Joe O’Brien

John Quinn

Mervyn Byrne

Helen Brennan